Recombinant Human DNASE1 Protein，His

DNASE1, or deoxyribonuclease I, is an enzyme that plays a crucial role in the degradation of extracellular DNA, primarily in the context of apoptosis and inflammation. Its primary function is to cleave DNA into smaller fragments, thus facilitating the removal of cellular debris and preventing potential autoimmune responses. Research on recombinant DNASE1 has gained significance due to its therapeutic potential in various diseases, particularly in conditions characterized by excessive DNA accumulation, such as cystic fibrosis. In cystic fibrosis patients, the accumulation of extracellular DNA from dead cells contributes to the thick mucus that obstructs airways, leading to chronic infection and inflammation. Recombinant DNASE1, such as the product Pulmozyme, has been developed to alleviate these symptoms by breaking down the viscous DNA, improving lung function and reducing infection rates. Furthermore, ongoing studies investigate the enzyme's applications in treating other pathologies, such as sepsis and certain types of cancer, where the regulation of extracellular DNA is crucial. The production of recombinant DNASE1 using modern biotechnological methods has allowed for increased yield and purity, enhancing its clinical efficacy. Research continues to explore the molecular mechanisms underlying DNASE1's activity and its interactions within the immune system, providing insights into novel therapeutic strategies for a range of inflammatory and autoimmune disorders. As our understanding of DNASE1 expands, it holds promise not only as a therapeutic agent but also as a tool for elucidating fundamental biological processes related to DNA metabolism and clearance.